Saracatinib inhibits TGF-β–induced phenotypic changes in human lung fibroblasts

ABSTRACT: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal disorder. Using an in-silico data-driven approach, we identified a robust connection between the transcriptomic perturbations in IPF disease and those induced by saracatinib, a selective Src kinase inhibitor, originally developed for oncological indications.We investigated the anti-fibrotic efficacy of saracatinib relative to nintedanib and pirfenidone in in vitro modele using normal human lung fibroblasts (NHLFs).

ORGANISM(S): Homo sapiens

PROVIDER: GSE178518 | GEO | 2022/08/30

REPOSITORIES: GEO